Phase I study of ABT-414 mono- or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM).
Volume: 33, Issue: 15_suppl, Pages: 2016 - 2016
Published: May 20, 2015
Abstract
2016 Background: GBM remains almost universally fatal and new therapies are needed. The epidermal growth factor receptor (EGFR) is a key oncogenic target. ABT-414, an antibody-drug conjugate with a toxic payload (monomethylauristatin F) targeted to activated EGFR, showed efficacy in preclinical models. We report the data of patients (pts) with recurrent GBM (Arms B + C) from an ongoing phase 1, open-label, 3-arm study (NCT01800695). Methods:...
Paper Details
Title
Phase I study of ABT-414 mono- or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM).
Published Date
May 20, 2015
Journal
Volume
33
Issue
15_suppl
Pages
2016 - 2016
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History